CR11501A - Tratamiento de cardiopatias usando b-bloqueantes - Google Patents

Tratamiento de cardiopatias usando b-bloqueantes

Info

Publication number
CR11501A
CR11501A CR11501A CR11501A CR11501A CR 11501 A CR11501 A CR 11501A CR 11501 A CR11501 A CR 11501A CR 11501 A CR11501 A CR 11501A CR 11501 A CR11501 A CR 11501A
Authority
CR
Costa Rica
Prior art keywords
cardiopatias
blockers
treatment
reversing
animals
Prior art date
Application number
CR11501A
Other languages
English (en)
Inventor
Gerald Beddies
Axel Schmidt
Original Assignee
Bayer Animal Health Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Animal Health Gmbh filed Critical Bayer Animal Health Gmbh
Publication of CR11501A publication Critical patent/CR11501A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invencion se refiere a un procedimiento para revertir la remodelacion cardiaca electrofisiologica de animales con cardiopatia. Mas especificamente, el procedimiento incluye administrar a un animal que lo necesite un bloqueante de adrenoceptores .
CR11501A 2007-12-27 2010-06-14 Tratamiento de cardiopatias usando b-bloqueantes CR11501A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1689107P 2007-12-27 2007-12-27

Publications (1)

Publication Number Publication Date
CR11501A true CR11501A (es) 2010-11-12

Family

ID=40456577

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11501A CR11501A (es) 2007-12-27 2010-06-14 Tratamiento de cardiopatias usando b-bloqueantes

Country Status (19)

Country Link
US (1) US20100305213A1 (es)
EP (1) EP2234609A1 (es)
JP (1) JP2011507918A (es)
KR (1) KR20100102640A (es)
CN (1) CN101909612A (es)
AU (1) AU2008342250A1 (es)
BR (1) BRPI0821483A2 (es)
CA (1) CA2710665A1 (es)
CO (1) CO6300936A2 (es)
CR (1) CR11501A (es)
EC (1) ECSP10010249A (es)
IL (1) IL205870A0 (es)
MX (1) MX2010006443A (es)
NI (1) NI201000096A (es)
RU (1) RU2010131022A (es)
SV (1) SV2010003595A (es)
TW (1) TW200942227A (es)
WO (1) WO2009083177A1 (es)
ZA (1) ZA201003867B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013113148A1 (zh) * 2012-01-30 2013-08-08 Lin Shuguang β3肾上腺素受体阻滞剂的抗肿瘤用途
PL3265126T3 (pl) 2015-03-03 2021-12-06 Saniona A/S Preparaty połączenia tesofensyny i metoprololu
US11235029B2 (en) 2017-03-09 2022-02-01 Temple University-Of The Commonwealth System of Higher Methods for treating heart failure with a TRKB agonist
US10744087B2 (en) 2018-03-22 2020-08-18 Incarda Therapeutics, Inc. Method to slow ventricular rate
CN110269938A (zh) * 2019-06-27 2019-09-24 山东省眼科研究所 一种减轻铜绿假单胞菌性角膜炎症的药物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040229901A1 (en) * 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
DE102006020604A1 (de) * 2006-05-02 2007-11-08 Bayer Healthcare Ag Flüssige Arzneimittelformulierung

Also Published As

Publication number Publication date
MX2010006443A (es) 2010-09-03
TW200942227A (en) 2009-10-16
SV2010003595A (es) 2011-01-14
WO2009083177A1 (en) 2009-07-09
CA2710665A1 (en) 2009-07-09
CO6300936A2 (es) 2011-07-21
KR20100102640A (ko) 2010-09-24
CN101909612A (zh) 2010-12-08
NI201000096A (es) 2011-03-23
ZA201003867B (en) 2011-08-31
BRPI0821483A2 (pt) 2015-06-16
US20100305213A1 (en) 2010-12-02
ECSP10010249A (es) 2010-07-30
IL205870A0 (en) 2010-11-30
JP2011507918A (ja) 2011-03-10
RU2010131022A (ru) 2012-02-10
EP2234609A1 (en) 2010-10-06
AU2008342250A1 (en) 2009-07-09

Similar Documents

Publication Publication Date Title
EA200900345A1 (ru) Замещенные ациланилиды и способы их применения
EA201190280A1 (ru) Производные l-(пиперидин-4-ил)пиразола в качестве модуляторов gpr 119
EA201290078A1 (ru) Гетероциклические соединения для ингибирования pask
ECSP13012611A (es) Derivados de pirazol-aminopirimidina como moduladores de la lrrk2
ECSP20046463A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
UY34165A (es) ?compuestos aldh-2 mitocondriales humanos para el tratamiento de la adicción?.
UY32923A (es) Compuestos policíclicos como antagonistas del receptor de ácido lisofosfatídico
EA200900177A1 (ru) Замещенные ациланилиды и способы их применения
EA201000559A1 (ru) Композиции и способы применения антител к склеростину
CR10948A (es) Compuestos triciclicos, composiciones y procedimientos
UY32502A (es) Agentes antihelmínticos y su utilización
BRPI0911577A8 (pt) derivados espiro-indol para o tratamento de doenças parasíticas.
PH12018500762A1 (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
CR11810A (es) Compuestos de 1,2-benzotiazolo utiles para combatir plagas animales
CR11501A (es) Tratamiento de cardiopatias usando b-bloqueantes
BR112012017994B8 (pt) composição líquida, uso de uma composição líquida, e, métodos para preparar uma composição líquida e para tratamento de um distúrbio
CR20110660A (es) Mezclas fungicidas
CY1115136T1 (el) Χρηση των χιτοζανων για την αυξηση του βαθμου αναπτυξης των νυχιων
AR086240A1 (es) Composiciones que comprenden un antimetabolito de glucosa, bha y/o bht
GT201300125A (es) 1h-pirazol-5-olato sódico sustituido
UY31717A1 (es) (pirazolilcarbonil) imidazolidinonas sustituidas y su uso
UY36688A (es) Compuestos de imidazotriazina
CY1119308T1 (el) Συνδυασμοι με ενα πεπτιδιο κυκλοποιημενου σκελετου
DOP2013000004A (es) Agentes terapeuticos 976
PA8806001A1 (es) Nuevo uso medico de las sales de propionato de 3-(2,2,2-trimetilhidrazinio) en el tratamiento de la enfermedad cardíaca isquémica

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)